ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,310.40
-0.20%
S&P ASX All Technology
3,765.60
-0.15%
Brent Oil
80.005
0.00%
US Dollar vs AUD
1.61499
0.00%
Bitcoin
105,088.80
0.64%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Immunome Inc (IMNM) Share Price

Immunome Inc

Immunome Inc (IMNM)

NASDAQ
9.99
0.13
(1.32%)
Closed 19 January 8:00AM
Delayed by 15 minutes
9.99
0.00
(0.00%)
After Hours: 8:10AM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
9.99
Bid
10.00
Offer
12.64
Volume
900,330
9.6901 Day's Range 10.385
8.97 52 Week Range 30.958
Market Cap
623.544M
Previous Close
9.86
Open
10.02
Last Trade
48
@
10.48
Last Trade Time
Financial Volume
US$ 9,074,098
VWAP
10.0786
Average Volume (3m)
825,494
Shares Outstanding
62,416,845
Dividend Yield
-
PE Ratio
-5.84
Earnings Per Share (EPS)
-1.71
Revenue
14.02M
Net Profit
-106.81M

About Immunome Inc

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious... Immunome Inc is a biopharmaceutical company. It is engaged in utilizing proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious disease, including COVID-19. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.immunome.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Immunome Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker IMNM. The last closing price for Immunome was US$9.86. Over the last year, Immunome shares have traded in a share price range of US$ 8.97 to US$ 30.958.

Immunome currently has 62,416,845 shares in issue. The market capitalisation of Immunome is US$615.43 million. Immunome has a price to earnings ratio (PE ratio) of -5.84.

Ask ADVFN Intelligence (AI)

IMNM Latest News

More News

Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Immunome to present at the 43rd Annual J.P. Morgan Healthcare Conference. Topline data for Phase 3 RINGSIDE study of varegacestat (formerly known as AL102) expected in second half of 2025. IND...

14 January 2025
Business Wire

Hummingbird Bioscience Licenses Novel Antibodies to Immunome

SAN FRANCISCO and SINGAPORE, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat...

08 January 2025
GlobeNewswire Inc.

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on January 2, 2025...

03 January 2025
Business Wire

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on December 2, 2024...

03 December 2024
Business Wire

Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome’s management will...

28 November 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

26 November 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

26 November 2024
Edgar (US Regulatory)

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

23 November 2024
Edgar (US Regulatory)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

15 November 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

14 November 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.37-3.5714285714310.3611.069.2487898510.02837351CS
4-1.11-1011.111.69.2485251810.56318218CS
12-2.11-17.438016528912.115.1258.9782549411.37961087CS
26-4.225-29.722124516414.21516.818.9771828912.70360754CS
52-3.86-27.870036101113.8530.9588.9779508415.25312562CS
156-0.31-3.0097087378610.330.9582.0932936513.69299738CS
260-5.67-36.206896551715.6663.782.0929012015.54823707CS

IMNM - Frequently Asked Questions (FAQ)

What is the current Immunome share price?
The current share price of Immunome is US$ 9.99
How many Immunome shares are in issue?
Immunome has 62,416,845 shares in issue
What is the market cap of Immunome?
The market capitalisation of Immunome is USD 615.43M
What is the 1 year trading range for Immunome share price?
Immunome has traded in the range of US$ 8.97 to US$ 30.958 during the past year
What is the PE ratio of Immunome?
The price to earnings ratio of Immunome is -5.84
What is the cash to sales ratio of Immunome?
The cash to sales ratio of Immunome is 44.48
What is the reporting currency for Immunome?
Immunome reports financial results in USD
What is the latest annual turnover for Immunome?
The latest annual turnover of Immunome is USD 14.02M
What is the latest annual profit for Immunome?
The latest annual profit of Immunome is USD -106.81M
What is the registered address of Immunome?
The registered address for Immunome is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
What is the Immunome website address?
The website address for Immunome is www.immunome.com
Which industry sector does Immunome operate in?
Immunome operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BTCTBTC Digital Ltd
US$ 8.2697
(73.73%)
61.45M
BDMDBaird Medical Investment Holdings Ltd
US$ 8.80
(62.36%)
18.63M
CRKNCrown Electrokinetics Corporation
US$ 0.1235
(54.96%)
764.86M
NUKKNukkleus Inc
US$ 29.97
(45.98%)
19.09M
GSITGSI Technology
US$ 3.97
(44.36%)
87.7M
DOGZDogness International Corporation
US$ 18.23
(-58.77%)
740.45k
ORKTOrangeKloud Technology Inc
US$ 3.02
(-24.88%)
21.08M
PMAXPowell Max Ltd
US$ 0.6364
(-23.31%)
4.17M
LGCBLinkage Global Inc
US$ 0.2876
(-22.27%)
890.66k
YYAIConnexa Sports Technologies Inc
US$ 0.8299
(-20.20%)
602.48k
CRKNCrown Electrokinetics Corporation
US$ 0.1235
(54.96%)
764.86M
GCTKGlucoTrack Inc
US$ 0.0852
(15.45%)
465.22M
RIMEAlgorhythm Holdings Inc
US$ 0.0406
(-4.02%)
387.23M
TGLTreasure Global Inc
US$ 0.2459
(14.75%)
267.1M
NVDANVIDIA Corporation
US$ 137.71
(3.10%)
201.4M

IMNM Discussion

View Posts
tw0122 tw0122 2 months ago
Looking good in some reverse head and shoulders at .85+4% and  .92-.99 up next. The world of DNA
👍️0
Monksdream Monksdream 4 months ago
IMNM under $15

👍️0
Monksdream Monksdream 10 months ago
IMNM 10Q due 3/22
👍️0
Monksdream Monksdream 10 months ago
IMNM new 52 week hi
👍️0
Monksdream Monksdream 1 year ago
IMNM new 52 week high
👍️0
OncoJock OncoJock 1 year ago
Agree.

Wish there were most posts on this board.

Wondering who might be the next big customer to sign a major discovery and commercialization contract with IMNM, after AbbVie?

Also wondering if IMNM is doing any discovery/testing/research related to bispecific antibodies, as opposed to antibody-drug conjugates. Bispecifics are HOT HOT HOT in lymphoma and myeloma.

-- OJ
👍️0
OncoJock OncoJock 1 year ago
agree
👍️0
Laster Laster 1 year ago
Hopefully the vote passed.
I think this biotech combined company can be a huge success.
Siegall has proven he can build a biotech company.
This will be fun to watch.
👍️ 1
Laster Laster 1 year ago
I believe merger news tomorrow along with huge financing.
Clay B. Siegall To become chairman and CEO of combined company.
He founded Seagen which just sold for $40 billion to Pfizer.
Their innovative technology from Professor Philip S. Low (Purdue University).
Look at Professor Low accomplishments. Unreal.
Watching closely because this might become a huge biotech company.
👍️ 1
wiwineguy wiwineguy 2 years ago
Ha, sold in fall of 21 for $25.
👍️0
makinezmoney makinezmoney 2 years ago
$IMNM: Now 10.40 !!!!!!!!!!!

Booooooooooooyakashaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa


Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies



GO $IMNM
👍️0
makinezmoney makinezmoney 2 years ago
$IMNM: Boooommmmmmmmmmmmmmm.......now $8.50


Offfffffffffff she goes.

Nice boomer



GO $IMNM
👍️0
Awl416 Awl416 2 years ago
Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies
👍️ 1
wiwineguy wiwineguy 3 years ago
you don't know crap majorbankz. you keep saying i "heard" this, and I "heard" that. can you be any more vague. stfu
👍️0
Harbor6460 Harbor6460 3 years ago
They cannot dilute on the bid. Only the ask
👍️0
Pedro2004 Pedro2004 4 years ago
Pulled down to under $20.00
👍️0
Pedro2004 Pedro2004 4 years ago
They pulled this down to under $21.00

I'm back-in at $21.00
👍️0
Major_Bankz Major_Bankz 4 years ago
$22.50 U worry too much, should be $25+ this afternoon IMO
👍️0
Pedro2004 Pedro2004 4 years ago
I thought this was going to break today. But it' just jumped over $22 -- let's see if that holds.
👍️0
Pedro2004 Pedro2004 4 years ago
This run could have broke $30 today. But the company killed-it.
👍️0
Major_Bankz Major_Bankz 4 years ago
yep, shorties portfolio will get destroyed here.
👍️0
Pedro2004 Pedro2004 4 years ago
The dilution is going to kill this run.
👍️0
Pedro2004 Pedro2004 4 years ago
Looks like the company is dumping shares on the bid.
👍️0
Major_Bankz Major_Bankz 4 years ago
I don't think PFE and MRNA can claim the same effectiveness for DELTA, plus time to buy is during development not after just like when MRNA was at $20. IMO
👍️0
Major_Bankz Major_Bankz 4 years ago
Delta is a BIG problem, IMNM may catch up to PFE and MRNA. IMO
👍️0
Major_Bankz Major_Bankz 4 years ago
Immunome was awarded a $17.6 million technology award from the U.S. Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency, to support Immunome’s COVID program.

Given the near-term potential for a resurgence of COVID-19 infections driven by emerging variants, Immunome intends to explore opportunities to expedite the development of this potential therapeutic. The Company plans to submit an IND application with the U.S. Food and Drug Administration (FDA) this quarter.
👍️0
Major_Bankz Major_Bankz 4 years ago
IMNM $21 Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing
👍️0

Your Recent History

NASDAQ
IMNM
Immunome
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads